• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Scorpius Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    7/23/25 4:10:19 PM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SCPX alert in real time by email
    false 0001476963 0001476963 2025-07-11 2025-07-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (date of earliest event reported): July 11, 2025

     

    Scorpius Holdings, Inc.

    (Exact name of registrant as specified in charter)

     

    Delaware

    (State or other jurisdiction of incorporation)

     

    001-35994 26-2844103
    (Commission File Number) (IRS Employer Identification No.)

     

    1305 E. Houston Street, Building 2

    San Antonio, TX 78205

    (Address of principal executive offices and zip code)

     

    (919) 240-7133

    (Registrant’s telephone number including area code)

     

    (Former Name and Former Address)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

     

      ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

      ¨ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)

     

      ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

      ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company  ¨  

     

    If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     
     
     
     

      

    Item 1.01. Entry Into a Material Definitive Agreement.

     

    Scorpius Holdings, Inc., a Delaware corporation (the “Company”), entered into an agreement (the “Note Amendment”) with an institutional investor (the “Investor”), effective July 11, 2025, to amend the 9% senior secured convertible note (the “Note”) in the aggregate original principal amount of $12,416,667 that the Company issued to the Investor on December 6, 2024, as amended on February 13, 2025 and May 1, 2025. Pursuant to the Note Amendment, the Company amended the conversion price of the Notes from $0.06 per share, subject to adjustment for stock splits, stock dividends, stock combinations, recapitalizations or other similar events, to the lower of (i) $0.06 per share, subject to adjustment for stock splits, stock dividends, stock combinations, recapitalizations or other similar events, and (ii) 55% of the average of the three lowest traded prices during the twenty (20) trading days immediately prior to the conversion date (the “Market Price”). The Note Amendment also removed the provision providing that the Company will seek stockholder approval (the “Second Stockholder Approval”) to amend the Company’s Third Amended and Restated Certificate of Incorporation, as amended, to either increase the Company’s authorized number of shares of common stock, par value $0.0002 per share (the “Common Stock”), or effect a reverse stock split to allow for complete conversion of the Note at the conversion price and removed the provision providing that until the Second Stockholder Approval is obtained and the amendment to the Company’s Third Amended and Restated Certificate of Incorporation, as amended is filed with the Secretary of State with the State of Delaware, the Investor may only convert $2,700,000 of principal amount of the Note.

     

    The Company does not have a sufficient number of authorized and unreserved shares of Common Stock to satisfy its obligation under the Note to reserve for issuance upon conversion of the Note 100% of the shares of Common Stock issuable under the Note.

     

    As a result of the Note Amendment, if the Note was to fully convert into shares of the Company’s Common Stock at a conversion price of $0.33, representing 55% of the Market Price of the Common Stock as of the date of this report, assuming no limitations on conversion, the Company would issue 345,243,790 shares of Common Stock upon conversion of the principal amount of the Notes, plus an additional 93,215,821 shares of Common Stock if interest and the Make-Whole Amount (as such term is defined in the Notes) is also converted into shares of Common Stock.

     

    On July 11, 2025, the Company also issued a non-convertible promissory note (the “Note”) in the principal amount of Four Hundred Eighty-Five Thousand Dollars ($485,000) to an institutional investor (the “Holder”). The Note accrues interest at the rate of 5.0% per annum and matures on the earlier of: (i) August 31, 2025; (ii) the consummation of a Corporate Event (as such term is defined in the Note); or (iii) when, upon or after the occurrence of an event of default under the Note. All payments by the Company upon maturity, redemption or prepayment of the Note shall include, together with all other amounts of principal and/or interest, a premium payment equal to 5% of the principal amount of the Note.

     

    The Note contains customary events of default, including if the Company or any of its subsidiaries, individually or in the aggregate, fails to pay indebtedness in excess of $150,000 due to any third party, subject to certain exceptions, or if an event of default occurs under any other outstanding promissory note of the Company. If at any time the Note is outstanding the Company consummates a subsequent Financing (as such term is defined in the Note), the Holder shall have the right, it its sole discretion, to require that the Company redeem the entire outstanding balance of the Note, together with all accrued interest thereon, using up to 100% of the gross proceeds of such Financing.

     

    The Company sold the Note in reliance upon an exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended and/or Regulation D promulgated thereunder.

     

    The foregoing description of the Note Amendment and Note are qualified in their entirety by reference to the full text of the Note Amendment and Note, copies of which are attached hereto as Exhibits 4.1 and 4.2, respectively, and which are incorporated herein in their entirety by reference.

     

    Item 2.03. Creation of a Direct Financial Obligation or an Obligation Under an Off-balance Sheet Arrangement of a Registrant.

     

    The information set forth under Item 1.01 above of this Current Report on Form 8-K is incorporated by reference in this Item 2.03.

     

    Item 3.02. Unregistered Sales of Equity Securities.

     

    The information set forth under Item 1.01 above of this Current Report on Form 8-K is incorporated by reference in this Item 3.02. The Note was issued pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D promulgated thereunder. The Note may not be offered or sold in the United States in the absence of an effective registration statement or exemption from the registration requirements.

     

    Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit
    Number
      Exhibit Description
    4.1   Form of Amendment to Senior Secured Convertible Note
    4.2   Form of Promissory Note
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

     

     
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: July 23, 2025

    SCORPIUS HOLDINGS, INC.

       
         
      By: /s/ Jeffrey Wolf
      Name:

    Jeffrey Wolf

      Title:

    Chairman, President and

    Chief Executive Officer

     

     

     

     

     

    Get the next $SCPX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SCPX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SCPX
    SEC Filings

    View All

    Scorpius Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - Scorpius Holdings, Inc. (0001476963) (Filer)

    7/30/25 8:00:26 AM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Scorpius Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - Scorpius Holdings, Inc. (0001476963) (Filer)

    7/23/25 4:10:19 PM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Scorpius Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - Scorpius Holdings, Inc. (0001476963) (Filer)

    7/3/25 4:01:55 PM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Thuan Tan Sze

    3 - Scorpius Holdings, Inc. (0001476963) (Issuer)

    3/12/25 4:07:02 PM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wolf Jeffrey Alan was granted 2,500,000 shares (SEC Form 4)

    4 - Scorpius Holdings, Inc. (0001476963) (Issuer)

    5/17/24 4:30:21 PM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCPX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tivic Health Enters GMP Manufacturing Validation Agreement with Scorpius BioManufacturing in Preparation for FDA Submission

    Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company, announced today it has entered a definitive agreement with Scorpius BioManufacturing to complete the GMP manufacturing validation of the lead candidate from its TLR5 program, Entolimod™, for treatment of Acute Radiation Syndrome, or ARS, in preparation for filing a Biological Licensing application, or BLA, with the U.S. Food & Drug Administration. Scorpius BioManufacturing, Inc. is an integrated contract development and manufacturing organization (CDMO) and subsidiary of Scorpius Holdings Inc. (OTC:SCPX), which will be the primary U.S. manufacturer for Entolimod™. Scorpius plans to utilize its scientific and tec

    5/14/25 8:30:00 AM ET
    $SCPX
    $TIVC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    Scorpius Holdings Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast Asia

    Operational Realignment Expected to Deliver Over $6 Million in Annual Cost Savings Company Exploring CDMO Expansion Opportunities in Southeast Asia San Antonio, TX , May 05, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (OTC:SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today provided a corporate update highlighting key strategic initiatives, including cost optimization measures expected to yield over $6 million in annualized savings and the Company's exploration of opportunities to expand operations into Southeast Asia through a potential biomanufacturing presence in Malaysia. Major Operational Cost Optimization Progr

    5/5/25 8:00:00 AM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Scorpius Holdings Provides 2024 Year-End Business Update; Implements Strategic Cost Reductions and Operational Streamlining

    SAN ANTONIO, April 30, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (OTC: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today provided strategic, financial, and operational updates for the year ended December 31, 2024. Jeff Wolf, CEO of Scorpius Holdings, Inc., stated, "The current biotech funding environment has created real headwinds for many of our clients, particularly when it comes to advancing drug development and clinical trials. In response, we took decisive steps to streamline our operations, reduce our cost structure, and refocus on our core CDMO capabilities. While the delay in our Form 10-K filing was not id

    4/30/25 4:05:30 PM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCPX
    Leadership Updates

    Live Leadership Updates

    View All

    Scorpius Holdings Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast Asia

    Operational Realignment Expected to Deliver Over $6 Million in Annual Cost Savings Company Exploring CDMO Expansion Opportunities in Southeast Asia San Antonio, TX , May 05, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (OTC:SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today provided a corporate update highlighting key strategic initiatives, including cost optimization measures expected to yield over $6 million in annualized savings and the Company's exploration of opportunities to expand operations into Southeast Asia through a potential biomanufacturing presence in Malaysia. Major Operational Cost Optimization Progr

    5/5/25 8:00:00 AM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Scorpius Holdings Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability

    DURHAM, N.C., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today provided a strategic, financial, and operational update for the third quarter ended September 30, 2024. Jeff Wolf, CEO of Scorpius Holdings, Inc., stated, "Scorpius continued to make strides in Q3, driven by key partnerships, disciplined financial management, and growth across our manufacturing and development services. We are proud to report a 142% year-over-year increase in revenue for the nine months ended September 30, 2024, reaching $5.2 million, which illustrates the demand fo

    11/14/24 4:15:00 PM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Scorpius Holdings Selected to Join Medical CBRN Defense Consortium to Advance Medical Countermeasures Against Chemical, Biological, Radiological, and Nuclear Threats

    DURHAM, N.C., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today announced that it has been selected to join the Medical CBRN Defense Consortium (MCDC), a key organization advancing the development of medical countermeasures and related technologies to protect U.S. military personnel and civilians from chemical, biological, radiological, and nuclear (CBRN) threats. The MCDC, established in 2015 under the U.S. Department of Defense (DoD), serves as a collaborative framework for government, industry, and academia to partner on cutting-edge medical solu

    10/2/24 8:00:00 AM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Scorpius Holdings Inc.

    SC 13G - Scorpius Holdings, Inc. (0001476963) (Subject)

    9/26/24 4:05:52 PM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Scorpius Holdings Inc.

    SC 13G - Scorpius Holdings, Inc. (0001476963) (Subject)

    9/6/24 4:01:41 PM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Scorpius Holdings Inc. (Amendment)

    SC 13D/A - Scorpius Holdings, Inc. (0001476963) (Subject)

    5/21/24 5:25:39 PM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care